A Consensus on Criteria for Cure of Acromegaly

被引：630

作者：

Giustina, A. ^{[1
]}

Chanson, P. ^{[2
,3
]}

Bronstein, M. D. ^{[4
]}

Klibanski, A. ^{[5
]}

Lamberts, S. ^{[6
]}

Casanueva, F. F. ^{[7
]}

Trainer, P. ^{[8
]}

Ghigo, E. ^{[9
]}

Ho, K. ^{[10
]}

Melmed, S. ^{[11
]}

机构：

[1] Univ Brescia, Dept Med & Surg Sci, I-25018 Montichiari, Italy

[2] Assistance Publ Hop Paris, Dept Endocrinol & Reprod Dis, F-94275 Le Kremlin Bicetre, France

[3] Univ Paris Sud 11, Dept Endocrinol & Reprod Dis, F-94275 Le Kremlin Bicetre, France

[4] Univ Sao Paulo, Sch Med, Neuroendocrine Unit, Div Endocrinol & Metab, BR-05311970 Sao Paulo, Brazil

[5] Massachusetts Gen Hosp, Neuroendocrine Unit, Boston, MA 02114 USA

[6] Erasmus MC, Dept Internal Med, Div Endocrinol, NL-3000 CA Rotterdam, Netherlands

[7] Univ Santiago de Compostela, Div Endocrinol CHUS, Dept Med, Santiago De Compostela 15782, Spain

[8] Christie Hosp, Dept Endocrinol, Manchester M20 4BX, Lancs, England

[9] Univ Turin, Div Endocrinol, I-10129 Turin, Italy

[10] Garvan Inst Med Res, Pituitary Res Unit, Sydney, NSW 2010, Australia

[11] Cedars Sinai Med Ctr, Dept Med, Los Angeles, CA 90048 USA

来源：

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM | 2010年 / 95卷 / 07期

关键词：

GROWTH-FACTOR-I; ACID-LABILE SUBUNIT; PREOPERATIVE OCTREOTIDE TREATMENT; DISEASE-RELATED MORBIDITY; GLUCOSE-TOLERANCE TEST; LONG-TERM; IGF-I; TUMOR SHRINKAGE; ORAL GLUCOSE; SOMATOSTATIN ANALOGS;

D O I：

10.1210/jc.2009-2670

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Objective: The Acromegaly Consensus Group met in April 2009 to revisit the guidelines on criteria for cure as defined in 2000. Participants: Participants included 74 neurosurgeons and endocrinologists with extensive experience of treating acromegaly. Evidence/Consensus Process: Relevant assays, biochemical measures, clinical outcomes, and definition of disease control were discussed, based on the available published evidence, and the strength of consensus statements was rated. Conclusions: Criteria to define active acromegaly and disease control were agreed, and several significant changes were made to the 2000 guidelines. Appropriate methods of measuring and achieving disease control were summarized. (J Clin Endocrinol Metab 95: 3141-3148, 2010)

引用

页码：3141 / 3148

页数：8

共 97 条

[1] Effects of preoperative octreotide treatment on different subtypes of 90 GH-secreting pituitary adenomas and outcome in one surgical centre [J].

Abe, T ;

Lüdecke, DK .

EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2001, 145 (02) :137-145

[2] Divergence between growth hormone and insulin-like growth factor-I concentrations in the follow-up of acromegaly [J].

Alexopoulou, Orsalia ;

Bex, Marie ;

Abs, Roger ;

T'Sjoen, Guy ;

Velkeniers, Brigitte ;

Maiter, Dominique .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2008, 93 (04) :1324-1330

[3] Long-term effects of lanreotide SR and octreotide LAR® on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly [J].

Amato, G ;

Mazziotti, G ;

Rotondi, M ;

Iorio, S ;

Doga, M ;

Sorvillo, F ;

Manganella, G ;

Di Salle, F ;

Giustina, A ;

Carella, C .

CLINICAL ENDOCRINOLOGY, 2002, 56 (01) :65-71

[4] Growth hormone response during oral glucose tolerance test:: The impact of assay method on the estimation of reference values in patients with acromegaly and in healthy controls, and the role of gender, age, and body mass index [J].

Arafat, Ayman M. ;

Moehlig, Matthias ;

Weickert, Martin O. ;

Perschel, Frank H. ;

Purschwitz, Johannes ;

Spranger, Joachim ;

Strasburger, Christian J. ;

Schoefl, Christof ;

Pfeiffer, Andreas F. H. .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2008, 93 (04) :1254-1262

[5] Diagnostic value of the acid-labile subunit in acromegaly: Evaluation in comparison with insulin-like growth factor (IGF) I, and IGF-binding protein-1, -2, and -3 [J].

Arosio, M ;

Garrone, S ;

Bruzzi, P ;

Faglia, G ;

Minuto, F ;

Barreca, A .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (03) :1091-1098

[6]

Attanasio Roberto, 2008, Endocr Pract, V14, P846

[7] Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly [J].

Ayuk, J ;

Clayton, RN ;

Holder, G ;

Sheppard, MC ;

Stewart, PM ;

Bates, AS .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (04) :1613-1617

[8] Two-year follow-up of acromegalic patients treated with slow release lanreotide (30 mg) [J].

Baldelli, R ;

Colao, A ;

Razzore, P ;

Jaffrain-Rea, ML ;

Marzullo, P ;

Ciccarelli, E ;

Ferretti, E ;

Ferone, D ;

Gaia, D ;

Camanni, F ;

Lombardi, G ;

Tamburrano, G .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (11) :4099-4103

[9] Ghrelin secretion in humans is sexually dimorphic, suppressed by somatostatin, and not affected by the ambient growth hormone levels [J].

Barkan, AL ;

Dimaraki, EV ;

Jessup, SK ;

Symons, KV ;

Ermolenko, M ;

Jaffe, CA .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (05) :2180-2184

[10] Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly [J].

Beauregard, C ;

Truong, U ;

Hardy, J ;

Serri, O .

CLINICAL ENDOCRINOLOGY, 2003, 58 (01) :86-91

← 1 2 3 4 5 6 7 8 9 10 →